Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulse Biosciences CS (PLSE)

Pulse Biosciences CS (PLSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,565,787
  • Shares Outstanding, K 67,989
  • Annual Sales, $ 350 K
  • Annual Income, $ -72,780 K
  • EBIT $ -77 M
  • EBITDA $ -76 M
  • 60-Month Beta 1.69
  • Price/Sales 4,193.95
  • Price/Cash Flow N/A
  • Price/Book 18.16

Options Overview Details

View History
  • Implied Volatility 97.31% (+11.85%)
  • Historical Volatility 76.04%
  • IV Percentile 7%
  • IV Rank 5.15%
  • IV High 352.51% on 11/20/25
  • IV Low 83.46% on 07/29/25
  • Expected Move (DTE 15) 0.94 (4.07%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 1,559
  • Open Int (30-Day) 1,849
  • Expected Range 22.07 to 23.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.32
  • Number of Estimates 1
  • High Estimate $-0.32
  • Low Estimate $-0.32
  • Prior Year $-0.25
  • Growth Rate Est. (year over year) -28.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.46 +32.07%
on 03/03/26
23.66 -2.54%
on 04/02/26
+4.21 (+22.33%)
since 03/02/26
3-Month
13.30 +73.38%
on 01/29/26
26.30 -12.32%
on 02/11/26
+9.67 (+72.22%)
since 01/02/26
52-Week
12.56 +83.60%
on 11/20/25
26.30 -12.32%
on 02/11/26
+6.33 (+37.84%)
since 04/02/25

Most Recent Stories

More News
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and...

PLSE : 23.05 (+0.09%)
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first...

PLSE : 23.05 (+0.09%)
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment.

PLSE : 23.05 (+0.09%)
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans...

PLSE : 23.05 (+0.09%)
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting

nPulse™ Vybrance™ System for soft tissue ablation, such as benign thyroid ablation, to be highlighted in podium presentation and product theatre presentation

PLSE : 23.05 (+0.09%)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation...

PLSE : 23.05 (+0.09%)
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present...

PLSE : 23.05 (+0.09%)
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates...

PLSE : 23.05 (+0.09%)
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months

PLSE : 23.05 (+0.09%)
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 23.05 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pulse Biosciences, Inc. is a medical device company. It is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling. NPES provide effective local tumor control and to initiate an adaptive immune response. The company deploy NPES platform applications...

See More

Key Turning Points

3rd Resistance Point 24.90
2nd Resistance Point 24.06
1st Resistance Point 23.55
Last Price 23.05
1st Support Level 22.20
2nd Support Level 21.36
3rd Support Level 20.85

See More

52-Week High 26.30
Last Price 23.05
Fibonacci 61.8% 21.05
Fibonacci 50% 19.43
Fibonacci 38.2% 17.81
52-Week Low 12.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.